Which has the lower trailing P/E, SNY or VRTX?

VRTX has the lower trailing P/E: SNY trades at 79.88 and VRTX at 32.41. P/E is one valuation measure and does not by itself establish which business is cheaper.

Which has grown faster, SNY or VRTX?

Over the past five years, VRTX grew revenue faster — SNY at a 4.96% CAGR versus VRTX at 13.57%.

Does SNY or VRTX pay a bigger dividend?

SNY pays a dividend (5.44% yield), while VRTX has no payments in the available dividend history.

Is SNY or VRTX more profitable?

VRTX runs the higher net margin — SNY at 8.10% versus VRTX at 34.89%.

How have SNY and VRTX total returns compared?

Over the past 10 years, SNY delivered 5.50% and VRTX delivered 19.33% annualized total return. Past performance doesn't predict future results.

Sanofi (SNY) vs Vertex Pharmaceuticals Incorporated (VRTX)

A side-by-side comparison of Sanofi and Vertex Pharmaceuticals Incorporated across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of September 3, 2026. Differences are shown without an overall score or investment verdict.

SNY

Sanofi

$106.45B

$44.33HealthcareDelayed quote: Sep 3, 2026, 4:00 PM EDT

VRTX

Vertex Pharmaceuticals Incorporated

$141.61B

$557.96HealthcareDelayed quote: Sep 3, 2026, 4:00 PM EDT

Total return — SNY vs VRTX

growth of $100 · dividends reinvested · last 10y

SNY +70.8% (+5.5%/yr)VRTX +481.2% (+19.2%/yr)VRTX compounded faster over this window

SNY VRTX

SNY vs VRTX: by the numbers

•VRTX is the larger company ($141.61B vs $106.45B market cap).
•VRTX trades at the lower trailing earnings multiple (32.41 vs 79.88 P/E), one valuation lens rather than an overall verdict.
•VRTX converts more revenue to profit (34.89% vs 8.10% net margin).
•VRTX grew revenue faster over the past five years (13.57% vs 4.96% CAGR).
•SNY pays a dividend (5.44% yield), while VRTX has no payments in the available dividend history.

Metrics side by side

Valuation

Metric	SNY	VRTX
P/E ratio	79.88	32.41
Forward P/E	N/A	29.70
P/S ratio	1.87	11.28
P/B ratio	1.35	7.03
EV / EBITDA	10.10	27.14
FCF yield	12.84%	2.67%

Profitability

Metric	SNY	VRTX
Gross margin	73.01%	86.04%
Operating margin	14.74%	38.59%
Net margin	8.10%	34.89%
ROE	5.82%	21.76%
ROIC	5.42%	17.33%

Dividends

Metric	SNY	VRTX
Dividend yield	5.44%	N/A
Payout ratio	64.36%	N/A

Growth (annualized)

Metric	SNY	VRTX
Revenue CAGR (5Y)	4.96%	13.57%
EPS CAGR (5Y)	-8.92%	8.17%
FCF CAGR (5Y)	12.83%	16.39%
Total return CAGR (5Y)	0.92%	22.82%

Frequently asked

Which has the lower trailing P/E, SNY or VRTX?: VRTX has the lower trailing P/E: SNY trades at 79.88 and VRTX at 32.41. P/E is one valuation measure and does not by itself establish which business is cheaper.
Which has grown faster, SNY or VRTX?: Over the past five years, VRTX grew revenue faster — SNY at a 4.96% CAGR versus VRTX at 13.57%.
Does SNY or VRTX pay a bigger dividend?: SNY pays a dividend (5.44% yield), while VRTX has no payments in the available dividend history.
Is SNY or VRTX more profitable?: VRTX runs the higher net margin — SNY at 8.10% versus VRTX at 34.89%.
How have SNY and VRTX total returns compared?: Over the past 10 years, SNY delivered 5.50% and VRTX delivered 19.33% annualized total return. Past performance doesn't predict future results.

Go deeper

Full SNY analysis Full VRTX analysis Interactive comparison tool

Dig into the metrics

Sanofi P/E ratio Vertex Pharmaceuticals P/E ratio Sanofi dividend yield Sanofi ROE Vertex Pharmaceuticals ROE Sanofi operating margin Vertex Pharmaceuticals operating margin Sanofi revenue growth Vertex Pharmaceuticals revenue growth Sanofi free cash flow Vertex Pharmaceuticals free cash flow

Sanofi & Vertex Pharmaceuticals appear in these rankings

Highest Dividend Yield Stocks Highest Operating Margin Stocks Highest FCF Yield Stocks Highest 10-Year Total Return Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified September 3, 2026.